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The identification of early biological changes associated with 
the psychotic disorder (PD) is important as it may provide 
clues to the underlying pathophysiological mechanisms. We 
undertook the first proteomic profiling of blood plasma sam-
ples of children who later develop a PD. Participants were 
recruited from the UK Avon Longitudinal Study of Parents 
and Children (ALSPAC) cohort who also participated in 
psychiatric assessment interviews at age 18. Protein expres-
sion levels at age 11 were compared between individuals who 
developed PD at age 18 (n = 37) with population-based age-
matched controls (n = 38). Sixty out of 181 plasma proteins 
profiled were found to be differentially expressed (P < .05) 
in children with an outcome of the PD. Thirty-four of these 
proteins were found to be differentially expressed following 
correction for multiple comparisons. Pathway analysis impli-
cated the complement and coagulation cascade. A second, 
targeted proteomic approach was used to verify these find-
ings in age 11 plasma from subjects who reported psychotic 
experiences at age 18 (n = 40) in comparison to age-matched 
controls (n = 66). Our findings indicate that the complement 
and coagulation system is dysregulated in the blood during 
childhood before the development of the PD.
Key words:  ALSPAC/complement/coagulation/plasma/
proteomics/psychotic disorder/schizophrenia
Introduction
There is firm evidence that the early identification and 
treatment of subjects with psychotic disorder (PD) 
significantly improve their clinical outcome.1 As clinical 
characteristics alone are of limited predictive value, there 
is a now a pressing need for further enhancement of pre-
dictive models to allow the earliest identification of sub-
jects who may later develop psychosis.2,3
Blood-based precursors of the PD may offer the oppor-
tunity to enhance predictive models and may provide 
important clues for our understanding of pathophysiologi-
cal cascades which may later be expressed as psychosis or 
PD. Our recent review of blood biomarkers in the PD 
schizophrenia points to a convergence of pathophysiologi-
cal mechanisms that involve the acute-phase response, glu-
cocorticoid receptor signalling, coagulation, and lipid and 
glucose metabolism.4 Furthermore, inflammatory cyto-
kines, chemokines, and growth factors have been assessed 
in the blood during the perinatal periods and during child-
hood in subjects who subsequently developed schizophre-
nia, and in those with a first-episode psychosis.5–9 These 
studies have, in general, demonstrated a picture of enhanced 
inflammatory tone during and preceding psychosis. While 
the basis of these changes is not clear, numerous risk fac-
tors for schizophrenia such as genetic background but also 
exposures to abuse, maternal stress during pregnancy, pre-
natal famine, obstetric complications, and adolescent can-
nabis use have all been described and hypothesized to lead 
to raised inflammatory tone.10 Post-mortem brain studies, 
albeit possibly confounded by many variables, have further-
more underpinned the evidence for a role of inflammation, 
suggesting that this process is involved during early but also 
later stages of the disorder.11–13
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One of the main challenges of the field is to identify 
differential profiles which can be measured prior to the 
clinical onset of the PD. Previous studies of the ALSPAC 
cohort, a prospective general population cohort based in 
Bristol area in South West England have characterized 
subgroups of subjects who developed PD and Psychotic 
Experiences (PEs)14 at age 18. These groups showed alter-
ations in cortical white matter microstructure,15 working 
memory,16 and raised inflammatory markers in child-
hood5 in subjects later developing PD and PE. Supported 
by this evidence, we employed a discovery proteomic 
study on blood plasma samples at age 11 in order to yield 
insights into the underlying protein pathways dysregu-
lated in children with PD outcomes at age 18. As expres-
sion of PEs can be considered as a liability phenotype 
for PDs and may involve the same etiopathogenesis,17 
we next quantified candidate proteins in blood samples 
of subjects at age 11 in a separate subsample from the 
ALSPAC cohort, and compared subjects who reported 
PEs at age 18 with matched control subjects without PEs 
at age 18 as an verification study.
Methods
For extended materials and methods, please refer to 
online supplementary methods.
Participants
The ALSPAC cohort is a prospective general population 
cohort, and a rich resource of demographic, environ-
mental, and clinical data on the individuals involved.18 
Written informed consent was obtained prior to taking 
the plasma samples. Ethical approval for the study was 
obtained from the ALSPAC Ethics and Law Committee 
and the Local Research Ethics Committees. Please note 
that the study website contains details of all the data that 
is available through a fully searchable data dictionary 
(http://www.bristol.ac.uk/alspac/researchers/access).
Measures of PE and PD
PEs were identified at 11 and 18 years through the face-to-
face, semi-structured Psychosis-Like Symptom (PLIKS) 
interview14 conducted by trained psychology graduates 
in assessment clinics, and were coded according to the 
definitions and rating rules for the Schedules for Clinical 
Assessment in Neuropsychiatry, Version 2.0 (Organisation 
1994). Interviewers rated PEs as not present, suspected 
or definitely psychotic. Cases of PD were defined as indi-
viduals with definite PEs that were not attributable to 
the effects of sleep or fever and when the PE occurred at 
least once per month over the past 6 months and caused 
severe distress, had a very negative effect on social/occupa-
tional function, or led to help seeking from a professional 
source.14 All subjects categorized at the interview as having 
a PD met diagnostic criteria for PDs as defined in both 
DSM-IV and ICD-10, given that they had regular psy-
chotic phenomena that were causing them severe distress 
or substantially impaired functioning.14 Control samples 
from age-matched individuals without suspected or defi-
nite PEs, or PD at age 18 were randomly selected to match 
cases (table 1). With regard to psychotropic drug use, 8 of 
the 37 subjects (21.6%) with PD and who provided plasma 
samples were on psychotropic medication at age 18. No 
subjects reported psychotropic drug use at age 11. Subjects 
categorized as having disorder in our study only included 
those whose PEs were not attributed to drug use.14
Study Design
We undertook a nested case-control study of the ALSPC 
cohort and chose to assess all available plasma samples 
from age 11 children with outcomes of PD or PE at age 18. 
Available plasma samples from controls of age-matched 
individuals were then randomly selected to arrive at the 
sample size for each analysis. The present study consisted 
of analyses of two datasets harboring mass-spectrome-
try-based proteomic profiles. (1) Discovery proteomic 
Table 1. Descriptive Information for ALSPAC Subjects Included in the PD and PE Studies
Psychotic Disorder (PD) 
Discovery Analysis
Psychotic Experiences (PE)
Verification Analysis
Cases Controls Cases Controls
Number 37 38 40 66
Gender 29F, 8M 28F, 10M 22F, 18M 27F, 39M
BMI at age 11, Mean (SD) 18.24 (3.39) 18.066 (2.69) 18.12 (2.72) 17.75 (2.52)
Ethnicity 28 W, 3 NW, 6 NA 37 W, 1 NA 37 W, 1 NW, 2 NA 63 W, 0 NW, 3 NA
PLIKS at age 12 20 none, 8 suspected, 9 definite 38 none 40 none 60 none, 6 NA
PLIKS at age 18 37 definite clinical None 29 = definite nonclinical, 
11 = sleep/fever
66 none
Note: For gender: F, female; M, male. Body mass index (BMI) at age 12 is reported, where missing BMI variables were replaced with the 
mean according to gender. For ethnicity: W, white; NW, non-white; NA, missing. PLIKS at age 12 and age 18 are reported, however, in 
this analyses, we used PLIKS at age 18 as the main outcome measure for our proteomic analysis.
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analysis was performed on n  =  37 individuals with an 
outcome of PD at age 18 vs n = 38 age-matched controls 
without PD or PE (table 1). (2) Hypothesis-driven prote-
omic analysis to confirm the discovery protein findings 
was performed on n  =  40 individuals with an outcome 
of PE at age 18 vs n  =  67 controls without PD or PE 
(table 1).
Blood Collection
For all participants, blood samples from nonfasting indi-
viduals were collected at approximately 11  years of age. 
Blood was collected in 7.5  ml Plasma Lithium-Heparin 
S-Monovette tubes (Sarsted). Once collected, samples were 
stored on ice for a maximum of 90  min until processed. 
After centrifugation, the plasma was stored in aliquots at 
−80C. All samples underwent a single freeze-thaw cycle to 
allow aliquotting prior to the study. The standard quality 
of the plasma samples was ensured by assessing the overall 
MS protein profile to facilitate the identification of outlier 
protein expression profiles (see supplementary figure S1).
High-Abundance Protein Depletion of Plasma Samples
To improve the dynamic range for proteomic analysis, 
40  µl of  plasma from each case was immunodepleted 
of the 14 most abundant proteins (alpha-1-antitrypsin, 
A1-acid glycoprotein, serum albumin, alpha2-macro-
globulin, apolipoprotein A-I, apolipoptrotein A-II, com-
plement C3, fibrinogen alpha/beta/gamma, haptoglobin, 
IgG A, IgG G, IgG M, transthyretin, and serotransfer-
rin) using the Agilent Hu14 Affinity Removal System 
(MARS) coupled to a high-performance liquid chroma-
tography (HPLC) system19 (supplementary methods).
Sample Preparation for Mass Spectrometry
Protein digestion and peptide purification was performed 
as previously described,20 and are further detailed in sup-
plementary methods.
Discovery Proteomic Analysis in PD
For the discovery proteomic analysis in PD (37 cases vs 38 
controls; see table 1), 5 μl from each sample was injected 
on a Thermo Scientific Q-Exactive mass spectrome-
ter, connected to a Dionex Ultimate 3000 (RSLCnano) 
chromatography system, and operated in data dependent 
analysis (DDA) mode, for label-free LC-MS/MS, which 
is standard proteomic profiling method for case/control 
clinical investigations.20–22 Please refer supplementary 
methods for further details.
Hypothesis-driven Proteomic Analysis in PE
For hypothesis-driven proteomic analysis of candidate 
proteins in a second subset of participants, we used 
targeted-data independent acquisition (DIA) analysis. 
Targeted-DIA is currently the gold standard for high-
throughput quantification of protein targets.23–25 For tar-
geted-DIA in the PE subset of participants (40 cases vs 
66 controls; table 1), 5 μl of  each sample was injected on 
the Thermo Scientific Q-Exactive, and data was acquired 
in DIA mode. The DIA isolation scheme and multiplex-
ing strategy were based on that from Egertson et al., in 
which five separate 4-m/z isolation windows are analyzed 
per spectrum26,27 (supplementary methods).
Bioinformatics and Statistical Analysis
Discovery Proteomic Analysis in PD. Label-free 
quantification for our discovery DDA files generated 
from the PD subjects was performed in Max Quant 
(v1.5.2.8),28,29 as described.20 Only proteins present in 
>80% of  samples in at least one group were taken for-
ward for quantification (supplementary table 1; n = 181 
proteins), whereby the data were log2 transformed and 
normalized (supplementary figure S1).30 Data man-
agement and analyses were then performed in R ver-
sion 3.0.1 (2013-05-16). Missing proteomic data was 
replaced with a random value from the normal dis-
tribution of  each protein that was created separately 
for cases and controls.31 Linear regression analyses 
were performed on all proteins with the subject sam-
ple as a random effect, adjusting for gender and BMI 
at age 11. We adjusted for BMI as the prevalence of 
obesity in people with mental illness has been reported 
to higher than the general population,32,33 and recent 
evidence suggests childhood BMI between the ages 
7 and 13  years is associated with risk of  schizophre-
nia.34 A  5% false discovery rate (FDR) threshold was 
applied using the “fdrtool” package in R, as previously 
described.35,36 The demographic and clinical data were 
tested for differences between case and control group 
using the Fisher’s Exact test.
Hypothesis-Driven Proteomic Analysis in PE. All 
DIA files from the PE analysis (see table  1 for groups) 
were analyzed in Skyline (V3.5.0; https://skyline.
gs.washington.edu), as detailed by Egertson et al.26,27 We 
aimed to verify; (1) the specific proteins identified as dif-
ferentially expressed following FDR from our “Discovery 
proteomic analysis in PD” and (2) the broader set and 
proteins from the complement and coagulation path-
ways which were generally implicated from the Discovery 
proteomic analysis in PD’. This was done in a separate 
ALSPAC subgroup of participants with a milder pheno-
type of PE (n = 40) but not PD at age 18, compared to 
controls (n = 66; table 1). For a full list of the fragments 
targeted and quantified please refer to supplementary 
table S2. All peptides and associated fragment ions were 
visually checked, and peak editing was undertaken where 
necessary (supplementary document 1). Preprocessing 
and statistical analysis of the fragment level data were 
300
English et al
undertaken in mapDIA37 (supplementary table S3), as 
detailed in supplementary methods.
Pathway Analysis
KEGG pathway analysis is traditionally performed on all 
proteins that are differentially expressed (P < .05) (http://
www.genome.jp/kegg/pathway.html) in order to identify 
coordinated changes in pathways and cellular processes 
at the level of the proteome, and this was therefore under-
taken on all proteins differentially expressed in the arising 
from the PD study. The STRING database (http://string-
db.org/)38 was used to analyze the protein–protein inter-
actions and pathway relationships within our dataset.
Results
Discovery Proteomic Analysis in PD
For the discovery proteomic analysis in PD (37 cases vs 38 
controls; table 1), we identified 345 proteins (FDR < 0.01), 
of which 181 were present in >80% of samples and were 
taken forward for analysis (supplementary table  1). 
Sixty proteins out of 181 were significantly differentially 
expressed between PD cases and controls (P < .05), fol-
lowing adjustment for gender and BMI as covariates 
(see results, table 2). Thirty-four proteins (A2M, TNXB, 
IGHM, CLEC3B, BCHE, GSN, ECM1, IGF2, C4BPB, 
CTBS, SERPINA7, VCAM1, LUM, GPLD1, HABP2, 
IGHG3, SEPP1, CFH, SERPINF1, F5, F9, IGFBP3, 
F12, CFD, CFI, LAMP2, CRTAC1, PCOLCE, AFM, 
PLG, COL6A3, C7, APOA2, CD109) remained signifi-
cant after FDR (table  2). The full list of proteins pro-
filed, and those that were differentially expressed between 
groups is provided in supplementary table 1.
Pathway Analysis
To identify potential protein pathways and processes 
whose expression is co-ordinately altered in PD, 
we uploaded the 60 significant proteins to KEGG 
for pathway analysis. The top pathway implicated 
was the “Complement and Coagulation Cascade” 
(figure 1a; Fisher’s exact test P = 8.56 × 10−32), followed 
by Staphylococcus aureus infection and Pertussis infec-
tion protein pathways (figure 1a). In addition, when the 
same proteins were analyzed using the STRING algo-
rithm, the set of  coagulation and complement proteins 
were found to cluster together as subnetworks (fig-
ure 1b), providing further evidence of  coordinated per-
turbation of  these pathways.
Hypothesis-Driven Proteomic Analysis in PE
These analyses aimed to verify and extend the findings 
of the discovery analysis of PD in a separate ALSPAC 
subgroup of participants with a milder phenotype of 
PE (n = 40) but not PD at age 18, compared to controls 
(n = 66; table 1). Two PE cases were excluded from the 
bioinformatics analysis due to poor chromatographic 
profiles.
We used a targeted-DIA approach (see supplementary 
document 1) to quantify the levels of the 34 FDR signif-
icant proteins in the PE group. Twenty-seven of the 34 
FDR candidates had peptides suitable for targeted-DIA 
analysis (supplementary table S3). We also used a tar-
geted-DIA approach to target the proteins which mapped 
to the complement and coagulation cascade in PD but 
which were not in the list of the 34 FDR significant pro-
teins (table  2). Thus of the total of 19 proteins which 
mapped to the complement and coagulation cascade 
(figure 1), we had already assessed 10 when undertaking 
our targeted-DIA assessment of the 34 FDR significant 
proteins, leaving 9 proteins (significant at P < .05) which 
mapped to this process (figure 1), and we assessed these 
9. Therefore a total of 36 protein candidates (27 + 9) were 
quantified in the hypothesis-driven PE study. Out of the 
36 targets, we confirmed the differential expression of 
10 proteins using a Bayesian latent variable model at a 
5% FDR threshold (C4BPA, A2M, PLG, AFM, CFH, 
IGHG3, VTN, GSN, C4BPB, and IGHM; supplemen-
tary table S3). The protein level DIA data illustrates that 
the direction of protein expression changes in the PD and 
PE phenotypes compared to controls was the same for all 
of these 10 proteins (figure 2).
Discussion
An urgent challenge in the field of psychosis is to under-
stand the pathophysiological basis of psychosis so that 
early prediction can be realized and earlier and more 
effective prevention and treatment options can be con-
sidered. We have undertaken the first discovery prote-
omic profiling study in early adolescence in order to 
identify differential plasma protein expression preceding 
PD. Using a unique prospective cohort, we investigated 
blood plasma samples obtained from children at age 11 
who went on to develop PD at age 18. In the samples 
collected at age 11, we identified a set of 34 proteins sig-
nificantly differentially expressed between children who 
developed PD vs age-matched population-based con-
trols (table 2). Seven of these 34 proteins (A2M, APOA2, 
C4BPB, CLECB3, GPLD1, IGHM, IGFBP3) have pre-
viously been implicated in blood-based biomarker studies 
of patients diagnosed with the PD schizophrenia.4 These 
proteins, therefore, might have potential value in predict-
ing the risk of and in contributing to future pathophysi-
ological models for PD. However, this will require robust 
identification of markers, calibration of risk prediction 
models, and testing in independent cohorts.
The information that can be derived from the broader 
pathway- or network-based picture of differential protein 
expression (rather than the individual proteins) is relevant 
to understanding the biological basis of the PD. Pathway 
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Table 2. Differential Protein Expression in Psychotic Disorder
Gene Names Protein Names Protein ID P Value FC in PD FDR
A2M Alpha-2-macroglobulin P01023 2.35E-05 −1.36 0.002452739084173
TNXB Tenascin-X P22105 6.78E-05 1.60 0.003010022721392
IGHM Ig mu chain C region P01871 8.93E-05 −1.49 0.003100233074614
CLEC3B Tetranectin P05452 0.000238536918096 1.21 0.005527149972427
BCHE Cholinesterase P06276 0.00028867379359 1.22 0.006016201946107
GSN Gelsolin P06396 0.001184331262904 1.13 0.013741065106703
ECM1 Extracellular matrix protein 1 Q16610 0.00156813706243 1.23 0.015289744574204
IGF2 Insulin-like growth factor II P01344 0.00185038627232 1.26 0.016146280605035
C4BPB C4b-binding protein beta 
chain
P20851 0.001968111624603 −1.31 0.016452583474952
CTBS Di-N-acetylchitobiase Q01459 0.002116574187167 1.23 0.016804037125592
SERPINA7 Thyroxine-binding globulin P05543 0.002123057983554 1.17 0.016818582457348
VCAM1 Vascular cell adhesion 
protein 1
P19320 0.002249659902707 1.34 0.01709034422445
LUM Lumican P51884 0.002278966387226 1.19 0.017150104571853
GPLD1 Phosphatidylinositol-glycan- 
specific phospholipase D
P80108 0.00234614616507 1.42 0.017282940815611
HABP2 Hyaluronan-binding protein 2 Q14520 0.002538350481953 1.17 0.017633778389896
IGHG3 Ig gamma-3 chain C region P01860 0.002874794375478 −1.27 0.018546283526309
SEPP1 Selenoprotein P P49908 0.003146451379488 1.21 0.019193243065463
CFH Complement factor H P08603 0.003414262231026 1.13 0.019765573474774
SERPINF1 Pigment epithelium-derived 
factor
P36955 0.003757243579115 1.13 0.02047865413338
F5 Coagulation factor V Q28107 0.004067608434137 1.27 0.021055629451341
F9 Coagulation factor IX P00740 0.004334224194447 1.13 0.021506865940923
IGFBP3 Insulin-like growth factor- 
binding protein 3
P17936 0.007644758410206 1.17 0.032388279082007
F12 Coagulation factor XII P00748 0.007824122898499 1.19 0.032887687197417
CFD Complement factor D P00746 0.008444673418423 1.35 0.034556546176356
CFI Complement factor I P05156 0.010003939954609 1.12 0.038384336560269
LAMP2 Lysosome-associated 
membrane glycoprotein 2
P13473 0.011818700619699 1.19 0.042278849036246
CRTAC1 Cartilage acidic protein 1 Q9NQ79 0.012282687547432 1.23 0.043191407027815
PCOLCE Procollagen C-endopeptidase 
enhancer 1
Q15113 0.012858286614664 1.19 0.044281235146809
AFM Afamin P43652 0.014449995361757 1.12 0.047073156606685
PLG Plasminogen P00747 0.014808887658904 1.14 0.047661474616677
COL6A3 Collagen alpha-3(VI) chain P12111 0.015123384190082 1.35 0.048165491709375
C7 Complement component C7 P10643 0.015253718180595 1.14 0.048371295829491
APOA2 Apolipoprotein A-II P02652 0.015768184543684 −1.35 0.049166640144774
CD109 CD109 antigen Q6YHK3 0.016302896370883 1.23 0.049965576376137
ACTG1 Actin, cytoplasmic 2 P63261 0.01842844064171 1.23 0.052893098007721
CD14 Monocyte differentiation 
antigen CD14
P08571 0.018648336393252 1.14 0.05317487598941
KLKB1 Plasma kallikrein P03952 0.019913520723869 1.11 0.054727223568396
KNG1 Kininogen-1 P01042 0.021034485331523 1.11 0.056011643691759
F5 Coagulation factor V P12259 0.021375886441285 1.14 0.056387118262621
SERPINF2 Alpha-2-antiplasmin P08697 0.024325248700793 1.09 0.059359684835652
C1S Complement C1s 
subcomponent
P09871 0.024366317843667 1.12 0.059397936011767
F2 Prothrombin P00734 0.024740545362472 1.12 0.059742847153768
APOA4 Apolipoprotein A-IV P06727 0.025696265563249 1.13 0.060594940495585
IGKV2D-40 Ig kappa chain V-II region 
TEW
A0A075B6R1 0.025902708420233 −1.20 0.060773774727794
LYVE1 Lymphatic vessel endothelial 
hyaluronic acid receptor 1
Q9Y5Y7 0.026443478521856 1.24 0.061233787247234
F13A1 Coagulation factor XIII 
A chain
P00488 0.027407334083503 1.14 0.062086047473999
S100A8 Protein S100-A8 P05109 0.030888403899574 1.24 0.065695245585865
ANPEP Aminopeptidase N P15144 0.030918599644144 1.22 0.065724623760281
VTN Vitronectin P04004 0.031818887929209 1.10 0.066586456714209
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analysis identified the Complement and Coagulation 
Cascade as the most significant process altered (figure 1), 
with a total of 19 proteins involved in the process being 
differentially expressed between groups. These comple-
ment and coagulation proteins included 3 decreased pro-
teins (A2M, C4BPA, C4BPB) and 16 increased proteins 
(C1R, C1S, C6, C7, CFD, CFH, CFI, F12, F13A1, F2, 
F5, F9, KLKB1, KNG1, PLG, SERPINF2) in children 
who developed PD. Due to significant overlap in proteins 
that mapped to the other top infection related processes 
in Staphylococcus and Pertussis infection, we focused 
our attention on complement and coagulation cascade. 
We followed the above discovery study with a hypothe-
sis-driven proteomic study of children who went on to 
develop PEs (rather than PD) at age 18. In this group, 
we confirmed the differential expression of 10 proteins 
which were altered in the PD group, and all of these 
changes were in the same direction as in the PD group 
(figure 2). Six of these targeted proteins were implicated 
in complement and coagulation (A2M, C4BPA, C4BPB, 
CFH, PLG, VTN), two in the immune system (IGHM 
and IGHG3), and one each in Vitamin E binding (AFM), 
and synaptic elimination and myelination (GSN). As PEs 
is a milder phenotype that PD, with about 8% of individ-
uals ultimately transitioning to PD,13 we consider these 
results to be supportive of our main findings.
The complement and coagulation cascade is part of 
the innate immune defense against infection, and the role 
of these processes in the pathophysiology of schizophre-
nia has gained attention in recent years. After decades of 
intensive research, collaborative GWAS efforts identified 
the strongest risk association for schizophrenia in the 
major histocompatibility complex (MHC)—best known 
for its role in immunity.39 Sekar et  al13 have recently 
shown that within this MHC region the strongest risks 
are associated with the complement 4 (C4) gene, which 
reflects the heritable impairment in the complement sys-
tem in schizophrenia. In this study, we found 9 comple-
ment proteins dysregulated in children preceding the 
onset of PD, including decreased C4BPA and C4BPB, 
and increased C1R, CFD, C1S, CFI, C6, C7, and CFH. 
The C4BPA and C4BPB proteins assemble together 
forming C4b-binding protein,which regulates the activa-
tion of the complement cascade, and also has a regulator 
role in the coagulation system. The coagulation system 
was also largely increased in expression in children pre-
ceding the onset of PD, including increased KNG1, 
PLG, KLKB1, F12, F9, F5, F13A1, SERPINF2, F2, 
and decreased A2M. In support, Li et al40 also reported 
the complement and coagulation cascade as the most sig-
nificant pathway implicated in plasma samples of drug 
naïve schizophrenia patients, and again reported on the 
reduced expression of C4BPB. Other blood-based pro-
teomic studies of first-episode psychosis support these 
findings.19,41,42 Dysfunction in coagulation has also been 
reported previously in schizophrenia4,43,44 and more 
recently by Hoirisch-Clapauch et  al,45 who observed 
that schizophrenia patients on chronic warfarin therapy 
showed remission of psychotic symptoms. The comple-
ment system is linked functionally with inflammation,46 
and within the brain has important functions in the reg-
ulation of synaptic plasticity.13,47–49 Our findings are thus 
in keeping with the literature implicating inflammation in 
major psychiatric disorders10,50 and with potential mecha-
nisms involved in complement and altered synaptic plas-
ticity.13,51–53 However, the functional relationship between 
Gene Names Protein Names Protein ID P Value FC in PD FDR
C4BPA C4b-binding protein alpha 
chain
P04003 0.034467677540817 −1.17 0.068973446582385
APOH Beta-2-glycoprotein 1 P02749 0.035328247276582 1.13 0.06970463250612
C6 Complement component C6 P13671 0.036921822018089 1.10 0.071005866471262
C1R Complement C1r 
subcomponent
P00736 0.03697367472293 1.13 0.07104710171526
CLU Clusterin P10909 0.037047254149251 1.09 0.071105498589918
COMP Cartilage oligomeric matrix 
protein
P49747 0.038053606817258 1.27 0.071890746567978
CPN2 Carboxypeptidase N subunit 2 P22792 0.039032541881775 1.11 0.07263130677403
ADIPOQ Adiponectin Q15848 0.041918375605006 1.28 0.076309890815356
ATRN Attractin O75882 0.045675287259397 1.09 0.080866376756604
VASN Vasorin Q6EMK4 0.047805918283872 1.15 0.083340993340051
RARRES2 Retinoic acid receptor 
responder protein 2
Q99969 0.048852426112363 1.15 0.084528878416831
Note: Label-free discovery proteomic was used to compare age 11 plasma samples from children with an outcome of PD at age 18 with 
age-matched healthy controls (n = 75). Sixty proteins were identified as significantly differentially expressed between cases and controls 
(ANCOVA, P < .05), following adjustment for gender and BMI as covariates (supplementary table 1). The gene name, protein name, 
accession, ANCOVA adjusted P value, fold change (FC) in disorder, and false discovery rate (FDR) values are listed for the 60 significant 
proteins which are sorted by FDR.
Table 2. Continued
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complement activation within the blood and the comple-
ment activation within the brain has not been elucidated, 
and hence we cannot draw a direct inference between our 
findings and brain function. In the light of our findings, 
future studies need to address this issue.
Our study has several limitations which should be men-
tioned. Firstly, it was based on a unique characterized 
cohort, and we could not access an exactly similar age-
matched sample in which we could perform a direct rep-
lication of the discovery analyses. However, we obtained 
supportive complementary data for our hypothesis-driven 
study using age 11 samples from a subject with PE out-
comes, rather than PD outcomes, from the same cohort. 
Nevertheless, it has been argued that PEs form a meas-
urable liability phenotype for PD and that PEs share (at 
least some of) the risk factors of PD, suggesting that their 
etiopathogenesis may involve similar biological cascades. 
Another potential weakness is that the subjects investi-
gated in this study were age 18 at the time of last clinical 
assessment and therefore have not yet gone through the 
full period of risk for developing a PD and hence our 
sample is not representative of all individuals with the 
PD. While future work will be required to address this, it 
is notable that our findings find significant support from 
the plasma proteomic biomarker literature of schizo-
phrenia which has implicated the complement and coag-
ulation pathways very consistently.4,17,29,30,31 Finally, while 
various approaches for bioinformatics analyses of DIA 
datasets are still under development, the methods we 
used are in line with recent advances in the bioinformatic 
Fig. 1. Differentially expressed proteins converge on complement and the coagulation cascade. (a) KEGG pathway analysis 60 proteins 
as differentially expressed between cases (n = 37) and controls (n = 38) identified the complement and coagulation cascade as the 
top process implicated (19 proteins; false discovery rate (FDR) 8.56e-32; (b) STRING network analysis provided strong evidence for 
co-regulation among coagulation and complement proteins, with the average interactions per protein being 3.65 (ie, average node degree) 
for 57 of the 60 proteins mapped. Proteins that were significant at the FDR level are marked with asterisks.
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Fig. 2. Bean plots of proteins identified as altered in the same direction in both the psychotic disorder (PD) and psychotic experience 
(PE) cohorts. Bean plots represent the log-transformed intensities in protein expression (y-axis) between cases and controls (x-axis) for 
both the PD (n = 75) discovery proteomic analysis (left), and PE (n = 106) hypothesis-driven proteomic analysis (right). Please note 
the scale on the y-axis differs between the PD and PE cohorts because different quantification methods were used to assess protein 
expression in each cohort (ie, DDA vs DIA data). Nevertheless, bean-plots representing the expression changes in complement and 
coagulation proteins (A2M, PLG, C4BPA, C4BPB, CFH, and VTN), and others (IGHM, IGHG3, GSN, and AFM) are altered in the 
same direction in both cohorts. These protein candidates may represent persistent early hallmarks of psychotic outcomes at age 18 in the 
general population.
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handling of DIA data by Teo et al.37 This tool considers 
the fragment level data as “repeated measurements” of 
the abundance of peptides and thus applies a sophisti-
cated hierarchical Bayesian algorithm37 for the analysis 
of DIA data (supplementary table 3).
In conclusion, our study which is the first to undertake a 
proteomic analysis of plasma in childhood from subjects 
who develop PD in early adulthood has identified altera-
tions in the complement and coagulation process. These 
changes are also present, but to a lesser extent, among 
subjects who go on to develop PE in early adulthood, 
suggesting that our findings may represent early changes 
associated with a vulnerability to psychosis. Further clar-
ification of the roles of these proteins and processes will 
be obtained from future studies which will test how base-
line levels of these proteins in subjects at ultra-high risk 
for PD relate to the varied clinical outcomes.54 Overall, 
our findings are indicative of the presence of a patho-
physiological process long before the development of the 
disorder, and suggest that blood-based profiles may be 
tested in larger population for their value in predicting 
later PD.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
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